These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 23529007)

  • 1. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.
    Liu X; Cheng D; Kuang Q; Liu G; Xu W
    Pharmacogenomics J; 2014 Apr; 14(2):120-9. PubMed ID: 23529007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.
    Zhang X; Yin JF; Zhang J; Kong SJ; Zhang HY; Chen XM
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):135-149. PubMed ID: 28585035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians.
    Cheng L; Li M; Hu J; Ren W; Xie L; Sun ZP; Liu BR; Xu GX; Dong XL; Qian XP
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):551-60. PubMed ID: 24448639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.
    Liu X; Cheng D; Kuang Q; Liu G; Xu W
    PLoS One; 2013; 8(3):e58489. PubMed ID: 23516488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.
    Hu ZY; Yu Q; Zhao YS
    Eur J Cancer; 2010 Jul; 46(10):1856-65. PubMed ID: 20335017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
    Liu D; Li J; Gao J; Li Y; Yang R; Shen L
    BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
    Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
    Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis.
    Zhu X; Ma R; Ma X; Yang G
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32936306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
    Yang C; Liu Y; Xi WQ; Zhou CF; Jiang JL; Ma T; Ye ZB; Zhang J; Zhu ZG
    Drug Des Devel Ther; 2015; 9():3677-83. PubMed ID: 26229432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
    Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
    Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
    Chen X; Liu L; Guo Z; Liang W; He J; Huang L; Deng Q; Tang H; Pan H; Guo M; Liu Y; He Q; He J
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1109-1117. PubMed ID: 28502040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
    Hazama S; Mishima H; Tsunedomi R; Okuyama Y; Kato T; Takahashi K; Nozawa H; Ando H; Kobayashi M; Takemoto H; Nagata N; Kanekiyo S; Inoue Y; Hamamoto Y; Fujita Y; Hinoda Y; Okayama N; Oba K; Sakamoto J; Oka M
    Cancer Sci; 2013 Dec; 104(12):1662-9. PubMed ID: 24033692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
    Fakih MG; Ross ME; Starostik P
    Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
    Xu C; Tang X; Qu Y; Keyoumu S; Zhou N; Tang Y
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):119-30. PubMed ID: 27220761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics and irinotecan therapy.
    Hahn KK; Wolff JJ; Kolesar JM
    Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.
    Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Chamnanphon M; Puangpetch A; Wongwaisayawan S; Sukasem C
    Drug Metab Pharmacokinet; 2016 Feb; 31(1):90-94. PubMed ID: 26830078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
    Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
    World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
    Ichikawa W; Uehara K; Minamimura K; Tanaka C; Takii Y; Miyauchi H; Sadahiro S; Fujita K; Moriwaki T; Nakamura M; Takahashi T; Tsuji A; Shinozaki K; Morita S; Ando Y; Okutani Y; Sugihara M; Sugiyama T; Ohashi Y; Sakata Y
    Br J Cancer; 2015 May; 112(10):1709-16. PubMed ID: 25880011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
    Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
    Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.